Hepatitis B: India's Silent Epidemic
India accounts for 11% of the world's Hepatitis B burden — approximately 40 million people are chronically infected, and most don't know it. Untreated chronic Hepatitis B leads to cirrhosis in 20–30% of patients and liver cancer in 5–10% over 20 years. The good news: modern antiviral therapy can suppress the virus to undetectable levels, preventing these complications entirely.
How Hepatitis B Spreads
- Mother to child (perinatal): Most common route in India — babies born to infected mothers have 90% chance of chronic infection without vaccination
- Unprotected sexual contact
- Contaminated needles: Injections, tattoos, piercings
- Blood transfusions (rare with modern screening)
- Household contact: Shared razors, toothbrushes
- NOT spread by casual contact, hugging, coughing, or sharing food
Acute vs. Chronic Hepatitis B
| Feature | Acute HBV | Chronic HBV |
|---|
| Duration | <6 months | >6 months |
| Symptoms | Jaundice, fatigue, nausea | Often none for years |
| Adults infected | 95% clear virus naturally | 5% become chronic |
| Infants infected | — | 90% become chronic |
| Treatment needed | Supportive care usually | Yes — antiviral therapy |
Symptoms to Watch For
Most people with chronic HBV have no symptoms until liver damage is advanced. When symptoms occur:
Symptoms
- Persistent fatigue
- Right upper abdominal discomfort
- Loss of appetite, nausea
- Joint pains (extrahepatic manifestation)
- Jaundice (advanced disease)
- Dark urine, pale stools
Who Should Get Tested
- Family members of HBV patients
- Anyone born to HBV-positive mother
- Healthcare workers
- Anyone with elevated liver enzymes (ALT/AST)
- Patients with unexplained fatigue
- Before starting immunosuppressive therapy
Diagnosis: What Tests We Run
- HBsAg (Hepatitis B Surface Antigen): Confirms active infection
- Anti-HBs: Confirms immunity (from vaccination or past infection)
- HBeAg / Anti-HBe: Indicates replication phase and immune status
- HBV DNA (Viral Load): Quantifies virus — guides treatment decisions
- LFT + ALT: Monitors liver inflammation
- FibroScan: Non-invasive liver stiffness measurement
- Ultrasound abdomen + AFP: 6-monthly for liver cancer surveillance
Treatment: Who Needs Antiviral Therapy?
Not every HBV carrier needs immediate treatment. Treatment decisions are based on HBV DNA level, ALT, liver fibrosis stage, and phase of infection.
First-Line Antiviral Medications
Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF): Preferred first-line agents. Once-daily oral tablet. Extremely potent, high barrier to resistance, safe for long-term use. TAF preferred in patients with kidney or bone concerns.
Entecavir (ETV): Equally effective, high barrier to resistance. Preferred in patients with kidney issues.
Pegylated Interferon-alfa (Peg-IFN): 48-week injection course. Suitable for select patients (young, high ALT, low DNA, genotype A/B). Can lead to HBsAg loss (functional cure) in 3–7%.
Treatment Goals
- Suppress HBV DNA to undetectable levels
- Normalize ALT (reduce liver inflammation)
- Prevent cirrhosis and liver cancer
- Achieve HBsAg loss (functional cure — rare but possible)
HBV and Pregnancy
Pregnant women with high HBV DNA (>200,000 IU/mL) need antiviral treatment in the third trimester to prevent transmission to the baby. The newborn receives HBV vaccine + HBIG within 12 hours of birth. Our gastroenterology team coordinates with the OBG department for comprehensive management.
Vaccination: The Best Prevention
Hepatitis B vaccine is safe, effective, and provides lifelong protection. The 3-dose schedule (0, 1, 6 months) achieves protective immunity in 95% of recipients. Unvaccinated household contacts of HBV patients should be vaccinated immediately.
Frequently Asked Questions
Is Hepatitis B curable?
Current antivirals achieve a "functional cure" (HBsAg loss) in only 3–7% of patients. However, they effectively suppress the virus long-term, prevent liver damage, and allow patients to live normal healthy lives. A sterilizing cure (complete elimination of HBV DNA from liver cells) remains the goal of ongoing research.
How long do I need to take antiviral medication?
Most patients with HBeAg-negative chronic HBV need lifelong therapy. HBeAg-positive patients who achieve HBeAg seroconversion may be able to stop after a defined consolidation period. Your doctor will guide you based on your individual phase and response.
Can I live a normal life with Hepatitis B?
Absolutely — with proper antiviral therapy and regular monitoring, the vast majority of HBV patients live completely normal lives with no restrictions on work, exercise, or social activities. Avoid alcohol and inform your doctor before starting any new medication.